Recent Company News

• 04:03 AM ET Oct 07, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (80 total)

• 04:03 AM ET Oct 05, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (117 total)

• 04:25 AM ET Oct 02, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (124 total)

• 07:06 AM ET Sep 30, 2026
  

  PureTech Health founded entity Celea Therapeutics to present two posters showcasing its deupirfenidone (LYT-100) program at the IPF Summit in Boston, MA (115.0000p, +1)

• 06:47 AM ET Sep 22, 2026
  

  Transcript Intelligence: PureTech Health Q2 Earnings Guidance

• 06:47 AM ET Sep 22, 2026
  

  Transcript Intelligence: PureTech Health Q2 Earnings Q&A

• 06:47 AM ET Sep 22, 2026
  

  Transcript Intelligence: PureTech Health Q2 Earnings Themes

• 03:32 AM ET Sep 22, 2026
  

  PureTech Health reports H1 net income $67.3M vs FactSet $67.2M [1 est] (124.0000p, +3)

• 02:06 AM ET Sep 21, 2026
  

  PureTech Health announces successful completion of End-of-Phase 1 meeting with FDA; receives FDA Fast Track designation for LYT-200 in combination with HMA for treatment of relapsed/refractory high-risk myelodysplastic syndromes (123.0000p, 0)

• 07:12 AM ET Sep 09, 2026
  

  Seaport Therapeutics reports topline results from Phase 1 Driving Simulation Trial of GlyphAllo in healthy volunteers; to announce topline data from the BUOY-1 trial in 1H27 ($24.06, 0.00)